Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 21, 2013Cardiovascular DiabetologyOpen Access

Sitagliptin treatment for 12 months significantly reduced HbA1c levels from 7.65% to 7.05% and improved sleep quality and diabetes symptoms in patients with type 2 diabetes.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does sitagliptin improve glycemic control, metabolic parameters, and quality of life in patients with type 2 diabetes mellitus?

Population

188 patients with type 2 diabetes mellitus with poor glycemic profiles despite receiving a medical diet…

Design

Cohort, open-label

Follow-up

12 months

Key result

Sitagliptin treatment for 12 months significantly reduced HbA1c levels from 7.65% to 7.05% and improved sleep quality and diabetes symptoms in patients with type 2 diabetes.

Authors

YSYoshiko SakamotoJOJun‐ichi OyamaHIHideo Ikeda

Discussion

Loading...

Member takes

Overview

DPP-4 inhibitors may aid glycemic control in Japanese T2DM; leaves open long-term CV safety and efficacy in randomized trials.

Study Design

Type

Observational (n=207)

Blinding

Open-label

Multicenter

Yes

Structured PICO

Does sitagliptin improve glycemic control, metabolic parameters, and quality of life in patients with type 2 diabetes mellitus?

P
Population
207 adults aged 20 years or older with type 2 diabetes and poor glycemic control (HbA1c ≥ 6.2%) despite standard therapy, followed for 12 months.
I
Intervention
Sitagliptin 50 to 100 mg oral once daily for 12 months
O
Outcome
Change in HbA1c levels and fasting plasma glucose (FPG) at 12 monthssurrogate

Main Result

Absolute Event Rate: 7.05% vs 7.65%

p-value: p=<0.001

Sitagliptin 50-100 mg daily for 12 months significantly improved glycemic control, blood pressure, lipid profiles, and sleep quality in Japanese patients with T2DM.

Limitations

  • Preliminary, single-arm study of a small number of subjects
  • Could not precisely evaluate subjects' adherence to their dosing regimens
  • Lack of a randomized control group

Cite This Study

Sakamoto et al. (2013) conducted an observational in Type 2 diabetes mellitus (n=207). Sitagliptin was evaluated on HbA1c levels at 12 months (p=<0.001). Sitagliptin treatment for 12 months significantly reduced HbA1c levels from 7.65% to 7.05% and improved sleep quality and diabetes symptoms in patients with type 2 diabetes.

synapsesocial.com/papers/6ab0d0b11a68cd0cef788ac8https://doi.org/10.1186/1475-2840-12-35
View Full Paper
Ask AI
Bookmark
Share